Serum-Biocon Deal Sees COVID Reality Tweak Even As Oxford’s Malaria Vaccine Holds Promise
HPV Vaccine India Tender Keenly Awaited
Executive Summary
Gains from its COVID-19 vaccine made Serum Institute’s founder the world’s richest healthcare billionaire. But the demand for boosters hasn’t materialized as expected, leading to a deal with Biocon being tweaked. Meanwhile, gains from India’s first indigenously-developed HPV vaccine and Oxford-partnered malaria vaccine seem imminent.
You may also be interested in...
Serum Scores A Double - HPV Vaccine In India, Novavax Vaccine In US
Serum Institute will supply initial doses of NVX-CoV2373 in the US, but late approvals have meant Novavax's vaccine is facing weak demand and surplus stocks in other parts of the world. Meanwhile, Serum has also secured a nod in India for the first indigenously-developed HPV vaccine, also the fifth globally.
Momentous Data For Oxford/Novavax Malaria Vaccine
A year to the day since the first dose of its COVID-19 vaccine was given, Oxford University's Jenner Institute has unveiled stellar findings from a Phase IIb trial of its malaria vaccine.
Zydus Looks To NASH Trials In Turkey, Generic Vascepa Launch In The US
Zydus, the only Indian company with an NCE for a range of chronic liver diseases, will add Turkey to the list of trial locations for NASH. It is also working “aggressively” to launch a generic to Amarin’s Vascepa after Revlimid and Trokendi generics drove record US sales in the fourth quarter.